ZA916661B - Stabilized solid chemical compositions - Google Patents

Stabilized solid chemical compositions

Info

Publication number
ZA916661B
ZA916661B ZA916661A ZA916661A ZA916661B ZA 916661 B ZA916661 B ZA 916661B ZA 916661 A ZA916661 A ZA 916661A ZA 916661 A ZA916661 A ZA 916661A ZA 916661 B ZA916661 B ZA 916661B
Authority
ZA
South Africa
Prior art keywords
water soluble
alkaline stabilizer
chemical compositions
solid chemical
stabilized solid
Prior art date
Application number
ZA916661A
Other languages
English (en)
Inventor
Pieter De Haan
De Haan Pieter
Cornelius Josephus Maria V Ven
Josephus Maria Van D Cornelius
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of ZA916661B publication Critical patent/ZA916661B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lubricants (AREA)
  • Developing Agents For Electrophotography (AREA)
ZA916661A 1990-09-13 1991-08-22 Stabilized solid chemical compositions ZA916661B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58185990A 1990-09-13 1990-09-13

Publications (1)

Publication Number Publication Date
ZA916661B true ZA916661B (en) 1992-06-24

Family

ID=24326864

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA916661A ZA916661B (en) 1990-09-13 1991-08-22 Stabilized solid chemical compositions

Country Status (14)

Country Link
EP (1) EP0475482B1 (ja)
JP (1) JP3153577B2 (ja)
KR (1) KR100196209B1 (ja)
AT (1) ATE112491T1 (ja)
AU (1) AU643920B2 (ja)
CA (1) CA2049811C (ja)
DE (1) DE69104453T2 (ja)
DK (1) DK0475482T3 (ja)
ES (1) ES2064887T3 (ja)
FI (1) FI104361B (ja)
IE (1) IE65274B1 (ja)
NZ (1) NZ239753A (ja)
PT (1) PT98955B (ja)
ZA (1) ZA916661B (ja)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022445A2 (en) * 1993-03-26 1994-10-13 Merkus Franciscus W H M Pharmaceutical compositions for intranasal administration of dihydroergotamine, apomorphine and morphine
AU750361B2 (en) * 1997-03-26 2002-07-18 Franciscus W.H.M. Merkus Nasal melatonin composition
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
US6691057B2 (en) 2001-02-26 2004-02-10 L.U.M. Gesellschaft Fur Labor- Umweltdiagnostic & Medizintechnik Mbh Method and device for accelerated stability analysis
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CA2491665A1 (fr) * 2004-12-24 2006-06-24 Louis Cartilier Formulation de comprime pour liberation soutenue de principe actif
NO347644B1 (no) 2006-05-04 2024-02-12 Boehringer Ingelheim Int Polymorfer
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
KR20190050871A (ko) 2010-06-24 2019-05-13 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
KR101985384B1 (ko) 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
RU2609198C1 (ru) * 2016-01-25 2017-01-30 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма имипрамина немедленного высвобождения и способ ее получения
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
KR102416406B1 (ko) * 2019-09-24 2022-07-04 주식회사 종근당 티카그렐러의 산 부가염을 포함하는 안정화된 약학 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2554736A (en) 1951-05-29 Tertiary aminoalkyl-iminodibenzyls
US2018410A (en) 1933-12-11 1935-10-22 Victor Chemical Works Dentifrice preparation
US2287699A (en) 1940-02-15 1942-06-23 Monsanto Chemicals Stabilized dicalcium phosphate
US3012852A (en) 1956-06-06 1961-12-12 Monsanto Chemicals Stabilized calcium phosphates and process therefor
DE1277222B (de) 1965-12-22 1968-09-12 Knapsack Ag Verfahren zur Stabilisierung von Dicalciumphosphatdihydrat
NL129434C (ja) 1966-03-12
US4128641A (en) 1975-07-31 1978-12-05 Hzi Research Center Inc. Tetracyclic psychotropic drug
DE2648061C2 (de) 1976-10-23 1982-11-04 Hoechst Ag, 6000 Frankfurt Verfahren zum Stabilisieren von Di-calciumhydrogenphosphatdihydrat
DE2741513A1 (de) 1977-09-15 1979-03-22 Benckiser Gmbh Joh A Verfahren zum stabilisieren von calciumhydrogenphosphat-dihydrat gegen hydrolyse
IE52274B1 (en) 1980-12-12 1987-09-02 Stauffer Chemical Co A process of compacting fine particles of calcium phosphate and the compacts obtained thereby
SE8103843L (sv) * 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US5004651A (en) 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
GB8920693D0 (en) * 1989-09-13 1989-10-25 Nicholas Kiwi Pty Ltd Non-effervescent ibuprofen compositions

Also Published As

Publication number Publication date
ES2064887T3 (es) 1995-02-01
FI914147A0 (fi) 1991-09-03
IE913054A1 (en) 1992-02-25
PT98955B (pt) 1999-02-26
AU643920B2 (en) 1993-11-25
KR100196209B1 (ko) 1999-06-15
PT98955A (pt) 1992-08-31
AU8341691A (en) 1992-03-19
EP0475482A1 (en) 1992-03-18
CA2049811A1 (en) 1992-03-14
FI104361B (fi) 2000-01-14
NZ239753A (en) 1992-10-28
DK0475482T3 (da) 1995-04-03
EP0475482B1 (en) 1994-10-05
DE69104453D1 (de) 1994-11-10
KR920005978A (ko) 1992-04-27
IE65274B1 (en) 1995-10-18
FI914147A (fi) 1992-03-14
DE69104453T2 (de) 1995-03-16
ATE112491T1 (de) 1994-10-15
CA2049811C (en) 2002-11-05
JPH0578236A (ja) 1993-03-30
JP3153577B2 (ja) 2001-04-09

Similar Documents

Publication Publication Date Title
ZA916661B (en) Stabilized solid chemical compositions
KR0136279B1 (ko) 일정수분을 함유하는 서방형 제제
ES8800041A1 (es) Un procedimiento para la produccion de una composicion farmaceutica de liberacion controlada de unidades individuales
KR910002670B1 (ko) 아모술랄롤 하이드로클로라이드 지속성 제제의 제조방법
KR920006909B1 (ko) 니트렌디핀을 함유하는 고상 약제의 제조 방법
AU751575B2 (en) Pharmaceutical levothyroxine preparation
EP0264259B1 (en) Stabilized pharmaceutical compositions
EG17589A (en) Process for preparing of 6-aryl 4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3h)-yl)-benzeneacetonitriles
AU742382B2 (en) Pharmaceutical preparation containing levothyroxine sodium
JPS5581596A (en) Composition for determining creatine kinase
NZ313576A (en) Stable solid formulation of enalapril salt and process for preparation thereof
HUT53664A (en) Process for producing enzyme inhibiting amino acid derivatives and pharmaceutical compositions comprising such compounds as active ingredient
AU576386B2 (en) 1h-indol-3-yl containing 1,3-dimethyl-1h-purine-2,6-diones
HU905725D0 (en) Process for producing 1,4-disubstituted 5-aryl-carbamoyl-4(6)-oxo-6(4)-oxido-pyrimidine-betaine derivatives and anthelmintic preparatives containing these compounds as active substance
HU895241D0 (en) Process for the preparation of substituted 1,3,5-triazin-trione derivatives and pharmaceutical compositions containing said compounds as active ingredient
MY137475A (en) Chemical compounds.
ZA821036B (en) Acesulfam-containing compositions,tablets on the basis thereof and process for the manufacture of these tablets
NO177484C (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat i form av myke kapsler
IL91986A0 (en) 2-azabicyclo(2.2.1)hept-5-ene-2-acetic acid,derivatives thereof and related compounds,process for the preparation of said compounds and the use of said compounds for the manufacture of n-phosphonomethylglycine
HUT56579A (en) Process for producing 19-norprogesterone derivatives alkylated at 17/21 position, as well as pharmaceutical compositions comprising such compounds as active ingredient
JPS55122713A (en) Tablet comprising antibacterial substance
ES8502094A1 (es) Un procedimiento para la preparacion de derivados de tetrahidroisoquinolina.
ES8206510A1 (es) Procedimiento para la preparacion del compuesto 3-metil-3- (o-metoxi-fenoxi)-benzo-2,4-dioxaciclohexanona
DE3261643D1 (en) New peptide, process for preparation thereof and use thereof
PT74540B (en) Process for preparing acid addition salts of 3,4-diacyloxi-alp ha-<(methylamino)-methyl>-benzylalcohol